 William Robinson
Concepts (851)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 94 | 2026 | 760 | 7.000 |
Why?
| | Skin Neoplasms | 49 | 2025 | 847 | 3.850 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 72 | 1.620 |
Why?
| | Mastocytosis | 3 | 2021 | 11 | 1.410 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2192 | 1.080 |
Why?
| | Spinal Fusion | 4 | 2022 | 260 | 0.890 |
Why?
| | Melanocytes | 7 | 2024 | 64 | 0.850 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2025 | 210 | 0.780 |
Why?
| | Mutation | 17 | 2022 | 4085 | 0.750 |
Why?
| | Vitiligo | 5 | 2024 | 42 | 0.730 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 61 | 0.720 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 79 | 0.710 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1519 | 0.710 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2025 | 225 | 0.690 |
Why?
| | Mucous Membrane | 2 | 2024 | 127 | 0.690 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.670 |
Why?
| | Piperazines | 7 | 2018 | 380 | 0.640 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 40 | 0.630 |
Why?
| | Spinal Fractures | 1 | 2020 | 73 | 0.600 |
Why?
| | Middle Aged | 94 | 2024 | 35762 | 0.590 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 172 | 0.580 |
Why?
| | Exome | 2 | 2017 | 227 | 0.580 |
Why?
| | Humans | 211 | 2026 | 144261 | 0.570 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 29 | 0.570 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 41 | 0.560 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.550 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.550 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 73 | 0.540 |
Why?
| | Osteoporosis | 2 | 2020 | 236 | 0.540 |
Why?
| | Humeral Head | 1 | 2017 | 20 | 0.540 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 16 | 0.530 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 40 | 0.520 |
Why?
| | Orthopedics | 1 | 2020 | 167 | 0.520 |
Why?
| | Skin Pigmentation | 4 | 2024 | 48 | 0.510 |
Why?
| | Intention | 1 | 2019 | 183 | 0.510 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2359 | 0.510 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 72 | 0.500 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 64 | 0.500 |
Why?
| | Granulocytes | 26 | 1988 | 80 | 0.490 |
Why?
| | Female | 120 | 2026 | 77976 | 0.490 |
Why?
| | Hematopoiesis | 24 | 1988 | 194 | 0.490 |
Why?
| | Databases, Factual | 4 | 2020 | 1484 | 0.480 |
Why?
| | MicroRNAs | 4 | 2023 | 700 | 0.480 |
Why?
| | Forecasting | 2 | 2017 | 388 | 0.480 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 17 | 0.460 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 118 | 0.460 |
Why?
| | Shoulder Joint | 1 | 2017 | 198 | 0.450 |
Why?
| | Osteoarthritis | 1 | 2017 | 195 | 0.450 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 100 | 0.440 |
Why?
| | Adult | 95 | 2025 | 40262 | 0.440 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1313 | 0.440 |
Why?
| | Phosphoproteins | 1 | 2017 | 343 | 0.430 |
Why?
| | Male | 101 | 2025 | 72035 | 0.420 |
Why?
| | Pyrimidines | 4 | 2008 | 532 | 0.420 |
Why?
| | Lysophospholipids | 2 | 2026 | 77 | 0.420 |
Why?
| | Aged | 63 | 2024 | 25850 | 0.410 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 37 | 0.410 |
Why?
| | Aged, 80 and over | 21 | 2021 | 8243 | 0.400 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.400 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3539 | 0.390 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.390 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 412 | 0.370 |
Why?
| | Milk, Human | 1 | 2014 | 172 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 40 | 0.350 |
Why?
| | Pyrroles | 3 | 2021 | 217 | 0.340 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 39 | 0.340 |
Why?
| | Triazines | 2 | 2021 | 49 | 0.340 |
Why?
| | Military Personnel | 1 | 2019 | 709 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 70 | 0.330 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1455 | 0.330 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2447 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1953 | 0.320 |
Why?
| | Lymph Node Excision | 5 | 2021 | 173 | 0.320 |
Why?
| | Sulfonamides | 4 | 2020 | 580 | 0.320 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 49 | 0.320 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 333 | 0.320 |
Why?
| | Genes, p16 | 3 | 2007 | 13 | 0.310 |
Why?
| | Adenocarcinoma | 5 | 2016 | 927 | 0.300 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 252 | 0.300 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 549 | 0.290 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1715 | 0.290 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 86 | 0.290 |
Why?
| | Uveal Neoplasms | 2 | 2026 | 16 | 0.290 |
Why?
| | Leukocytes | 14 | 1986 | 295 | 0.290 |
Why?
| | Lumbosacral Region | 2 | 2019 | 59 | 0.280 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 9 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 199 | 0.280 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 321 | 0.280 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 32 | 0.270 |
Why?
| | Treatment Outcome | 15 | 2022 | 11643 | 0.270 |
Why?
| | Cyclins | 1 | 2008 | 84 | 0.270 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 623 | 0.270 |
Why?
| | Nitrophenols | 3 | 2017 | 29 | 0.270 |
Why?
| | Quality Improvement | 2 | 2018 | 1285 | 0.260 |
Why?
| | Tretinoin | 4 | 2023 | 124 | 0.260 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 54 | 0.260 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 68 | 0.260 |
Why?
| | Pyrazoles | 2 | 2021 | 509 | 0.260 |
Why?
| | Tamoxifen | 3 | 2016 | 217 | 0.250 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 339 | 0.250 |
Why?
| | Prognosis | 14 | 2024 | 4278 | 0.250 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 45 | 0.240 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 93 | 0.240 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2026 | 53 | 0.240 |
Why?
| | Interferon-alpha | 6 | 2006 | 197 | 0.240 |
Why?
| | Hair Color | 2 | 2024 | 14 | 0.230 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 370 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 240 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 35 | 0.220 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 163 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 928 | 0.220 |
Why?
| | Liposarcoma | 1 | 2005 | 31 | 0.220 |
Why?
| | Epidermis | 2 | 2024 | 157 | 0.220 |
Why?
| | Follow-Up Studies | 12 | 2020 | 5389 | 0.220 |
Why?
| | Mice | 29 | 2026 | 18329 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 388 | 0.220 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 30 | 0.210 |
Why?
| | Intestine, Small | 2 | 2024 | 166 | 0.210 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1054 | 0.210 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 387 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 57 | 0.210 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.210 |
Why?
| | Piperidines | 2 | 2018 | 217 | 0.200 |
Why?
| | Lymph Nodes | 1 | 2006 | 502 | 0.200 |
Why?
| | Dacarbazine | 7 | 2012 | 100 | 0.200 |
Why?
| | Mice, Nude | 4 | 2020 | 682 | 0.200 |
Why?
| | Hair Follicle | 3 | 2020 | 48 | 0.200 |
Why?
| | Genomics | 4 | 2024 | 833 | 0.200 |
Why?
| | Exons | 3 | 2019 | 358 | 0.200 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1461 | 0.200 |
Why?
| | Melatonin | 3 | 1994 | 163 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 917 | 0.200 |
Why?
| | Stem Cells | 4 | 2017 | 625 | 0.200 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 220 | 0.190 |
Why?
| | Burns | 7 | 1997 | 376 | 0.190 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 21 | 0.190 |
Why?
| | Flavonoids | 1 | 2003 | 87 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 162 | 0.190 |
Why?
| | Pedigree | 3 | 2024 | 513 | 0.180 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 431 | 0.180 |
Why?
| | Retrospective Studies | 17 | 2025 | 17009 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 881 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 259 | 0.180 |
Why?
| | Lordosis | 1 | 2022 | 16 | 0.180 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 157 | 0.180 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.180 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 420 | 0.180 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 7 | 0.180 |
Why?
| | Clone Cells | 7 | 2010 | 266 | 0.180 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 41 | 0.180 |
Why?
| | Animals | 35 | 2026 | 38030 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 1137 | 0.170 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 628 | 0.170 |
Why?
| | Registries | 3 | 2020 | 2382 | 0.170 |
Why?
| | Liver Neoplasms | 3 | 2026 | 780 | 0.170 |
Why?
| | Risk Factors | 8 | 2020 | 10699 | 0.160 |
Why?
| | Signal Transduction | 8 | 2026 | 5221 | 0.160 |
Why?
| | Interleukin-1 | 2 | 2019 | 961 | 0.160 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1782 | 0.160 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1044 | 0.160 |
Why?
| | Sonication | 1 | 2020 | 12 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 39 | 0.160 |
Why?
| | Leukemia | 8 | 1988 | 245 | 0.160 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 29 | 0.160 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 83 | 0.160 |
Why?
| | Turner Syndrome | 1 | 2001 | 63 | 0.160 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1495 | 0.150 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 3 | 0.150 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 919 | 0.150 |
Why?
| | Finger Joint | 1 | 2019 | 9 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2020 | 119 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 71 | 0.150 |
Why?
| | Finger Phalanges | 1 | 2019 | 13 | 0.150 |
Why?
| | beta Catenin | 2 | 2020 | 252 | 0.150 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 442 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 99 | 0.150 |
Why?
| | Heart Neoplasms | 2 | 1999 | 55 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 59 | 0.150 |
Why?
| | Bone Density | 2 | 2020 | 482 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2019 | 34 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2020 | 141 | 0.140 |
Why?
| | RNA | 2 | 2016 | 939 | 0.140 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 37 | 0.140 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 27 | 0.140 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.140 |
Why?
| | Ipilimumab | 1 | 2018 | 39 | 0.140 |
Why?
| | Reoperation | 2 | 2019 | 629 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 67 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2022 | 3592 | 0.140 |
Why?
| | Hospital Costs | 1 | 2018 | 124 | 0.140 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 48 | 0.130 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Immune Tolerance | 3 | 2026 | 379 | 0.130 |
Why?
| | Receptors, Androgen | 1 | 1998 | 153 | 0.130 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 95 | 0.130 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 77 | 0.130 |
Why?
| | Biofilms | 1 | 2020 | 278 | 0.130 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 320 | 0.130 |
Why?
| | Adolescent | 35 | 2025 | 22281 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 196 | 0.130 |
Why?
| | Low Back Pain | 1 | 2019 | 106 | 0.130 |
Why?
| | Burns, Electric | 3 | 1986 | 26 | 0.130 |
Why?
| | Bone Marrow | 14 | 1983 | 304 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 248 | 0.120 |
Why?
| | Cisplatin | 4 | 2006 | 334 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2018 | 253 | 0.120 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 23 | 0.120 |
Why?
| | Membrane Proteins | 4 | 2020 | 1165 | 0.120 |
Why?
| | Freezing | 4 | 2014 | 85 | 0.120 |
Why?
| | Benzamides | 2 | 2008 | 224 | 0.120 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.120 |
Why?
| | Apoptosis | 4 | 2018 | 2430 | 0.120 |
Why?
| | Pain Measurement | 1 | 2019 | 552 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 271 | 0.120 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 294 | 0.120 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 82 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2000 | 736 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 261 | 0.120 |
Why?
| | Adenine | 1 | 2018 | 339 | 0.120 |
Why?
| | Drug Synergism | 4 | 2018 | 357 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 127 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 402 | 0.120 |
Why?
| | Interferon Type I | 4 | 1994 | 145 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 99 | 0.110 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2637 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 981 | 0.110 |
Why?
| | Cell Cycle | 3 | 2010 | 596 | 0.110 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1318 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 842 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1322 | 0.110 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 81 | 0.110 |
Why?
| | Leukocyte Count | 20 | 1988 | 316 | 0.110 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 19 | 0.110 |
Why?
| | Fenretinide | 1 | 2014 | 3 | 0.110 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 556 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 268 | 0.110 |
Why?
| | Desiccation | 1 | 2014 | 24 | 0.110 |
Why?
| | Cell Division | 11 | 1998 | 766 | 0.110 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2026 | 40 | 0.110 |
Why?
| | Survival Analysis | 6 | 2010 | 1382 | 0.110 |
Why?
| | Cell Survival | 8 | 2018 | 1098 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 698 | 0.110 |
Why?
| | Lymphoma | 4 | 1991 | 232 | 0.110 |
Why?
| | Survival Rate | 8 | 2024 | 2088 | 0.100 |
Why?
| | Peptides | 2 | 2008 | 995 | 0.100 |
Why?
| | Cohort Studies | 3 | 2024 | 5935 | 0.100 |
Why?
| | Child | 17 | 2025 | 22537 | 0.100 |
Why?
| | Perineum | 1 | 1993 | 37 | 0.100 |
Why?
| | Basigin | 1 | 2013 | 24 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 457 | 0.100 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2026 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.100 |
Why?
| | Internet | 1 | 2018 | 698 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 120 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 55 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2494 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 131 | 0.090 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 8 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 322 | 0.090 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 58 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 985 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | BRCA1 Protein | 1 | 2013 | 81 | 0.090 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.090 |
Why?
| | Vitamins | 1 | 1994 | 178 | 0.090 |
Why?
| | Alleles | 2 | 2022 | 878 | 0.090 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 20 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 177 | 0.090 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.090 |
Why?
| | Pyrimidinones | 2 | 2025 | 126 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 974 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 641 | 0.090 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 129 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 824 | 0.090 |
Why?
| | Peer Review | 1 | 2012 | 44 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 55 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3157 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 405 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2917 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 44 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 33 | 0.090 |
Why?
| | Keratinocytes | 2 | 2024 | 248 | 0.080 |
Why?
| | History, 21st Century | 1 | 2012 | 219 | 0.080 |
Why?
| | Agranulocytosis | 6 | 1986 | 30 | 0.080 |
Why?
| | United States | 3 | 2020 | 15876 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 324 | 0.080 |
Why?
| | Cyclosporine | 1 | 1991 | 265 | 0.080 |
Why?
| | Pancreatitis | 1 | 1991 | 142 | 0.080 |
Why?
| | Blast Crisis | 1 | 1990 | 35 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 2111 | 0.080 |
Why?
| | Time Factors | 15 | 2019 | 7155 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 255 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3637 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 246 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 355 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 121 | 0.080 |
Why?
| | Neoplasms | 5 | 2018 | 2870 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 768 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 12 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4146 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1367 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 780 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2730 | 0.070 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 479 | 0.070 |
Why?
| | Osteonecrosis | 2 | 1986 | 23 | 0.070 |
Why?
| | Cell Differentiation | 7 | 2015 | 2048 | 0.070 |
Why?
| | Lithium | 5 | 1986 | 42 | 0.070 |
Why?
| | Neutrophils | 8 | 1988 | 1134 | 0.070 |
Why?
| | Cyclin D | 1 | 2008 | 8 | 0.070 |
Why?
| | Lymphocytes | 7 | 2006 | 382 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2013 | 627 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 142 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2187 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1739 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 347 | 0.070 |
Why?
| | Risk | 2 | 2019 | 909 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 80 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 851 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2877 | 0.070 |
Why?
| | Skull | 2 | 1986 | 155 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 25 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 193 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Australia | 2 | 2023 | 286 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 15 | 0.060 |
Why?
| | Computational Biology | 3 | 2019 | 680 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 152 | 0.060 |
Why?
| | Oligosaccharides | 1 | 2007 | 60 | 0.060 |
Why?
| | Cell Movement | 5 | 2015 | 965 | 0.060 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.060 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.060 |
Why?
| | Factor VIII | 1 | 1987 | 104 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 245 | 0.060 |
Why?
| | Cell Self Renewal | 2 | 2017 | 53 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2008 | 509 | 0.060 |
Why?
| | Vaccinia virus | 2 | 1998 | 34 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 529 | 0.060 |
Why?
| | Disease Progression | 2 | 2013 | 2840 | 0.060 |
Why?
| | Education, Medical | 1 | 1990 | 273 | 0.060 |
Why?
| | Health Education | 1 | 1990 | 357 | 0.060 |
Why?
| | Quinazolines | 1 | 2008 | 266 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 147 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1327 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 13990 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 122 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 43 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1820 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 462 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 25 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 22 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 22 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 422 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 90 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 164 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 107 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 23 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 147 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 573 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 6 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 68 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3857 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1497 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 2 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1047 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 59 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 28 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 113 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 17 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 508 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 704 | 0.050 |
Why?
| | Karyotyping | 4 | 1994 | 106 | 0.050 |
Why?
| | Forearm | 1 | 1985 | 139 | 0.050 |
Why?
| | Infant | 2 | 2019 | 10022 | 0.050 |
Why?
| | Axilla | 1 | 2004 | 51 | 0.050 |
Why?
| | Hand Injuries | 1 | 1985 | 33 | 0.050 |
Why?
| | Wrist | 1 | 1985 | 60 | 0.050 |
Why?
| | Burns, Chemical | 1 | 1985 | 32 | 0.050 |
Why?
| | Skin Transplantation | 1 | 1985 | 85 | 0.050 |
Why?
| | Macrophages | 4 | 1988 | 1510 | 0.050 |
Why?
| | Protein Transport | 2 | 2018 | 441 | 0.050 |
Why?
| | Acute Disease | 6 | 1991 | 1028 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 200 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 117 | 0.050 |
Why?
| | Blood Cell Count | 5 | 1995 | 54 | 0.050 |
Why?
| | Monocytes | 5 | 1983 | 538 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2143 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 15 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1732 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 337 | 0.050 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 688 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 63 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 107 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 478 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 198 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 397 | 0.050 |
Why?
| | Urine | 4 | 1973 | 62 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2929 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 91 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 28 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 852 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 68 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 109 | 0.050 |
Why?
| | Mice, Inbred C57BL | 5 | 2026 | 5988 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1468 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 155 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 484 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 272 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 104 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 968 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 2 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 59 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 376 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 24 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 53 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 210 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 52 | 0.040 |
Why?
| | Leukocytosis | 4 | 1974 | 32 | 0.040 |
Why?
| | Neck Pain | 1 | 2021 | 30 | 0.040 |
Why?
| | Antigens | 2 | 1983 | 347 | 0.040 |
Why?
| | Gene Expression | 3 | 2008 | 1487 | 0.040 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1050 | 0.040 |
Why?
| | Isotretinoin | 2 | 1994 | 26 | 0.040 |
Why?
| | Incidence | 3 | 2009 | 2870 | 0.040 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 17 | 0.040 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 43 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 1983 | 253 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 123 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4556 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 353 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 23 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 14 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 557 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 847 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 316 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 8 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 5 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 55 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 13 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 120 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 96 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 56 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 682 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 148 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 30 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3313 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 220 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 33 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 21 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 824 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3166 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 22 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2829 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 48 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 140 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 26 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 266 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 90 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2026 | 3119 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 164 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1180 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 44 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 146 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 36 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 100 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2019 | 125 | 0.030 |
Why?
| | Arthritis | 1 | 2019 | 96 | 0.030 |
Why?
| | Heterografts | 1 | 2018 | 143 | 0.030 |
Why?
| | Chromosome Deletion | 2 | 1994 | 124 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 133 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 496 | 0.030 |
Why?
| | Levamisole | 1 | 1977 | 21 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 372 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 186 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 37 | 0.030 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 81 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 166 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 380 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 79 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 166 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 116 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 151 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 421 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 67 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 172 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 18 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 40 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 52 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 66 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 319 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 205 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 135 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 77 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 14 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 69 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 974 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 160 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 75 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1264 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 437 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 171 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 778 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 387 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 20 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 183 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 194 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 66 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 257 | 0.030 |
Why?
| | Veins | 1 | 1995 | 68 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 8 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 8 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 273 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 423 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 33 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2270 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 67 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 363 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 102 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 542 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 15 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 338 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 20 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 28 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 43 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 19 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 13 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 127 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 42 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 380 | 0.020 |
Why?
| | Anus Neoplasms | 1 | 1993 | 32 | 0.020 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 122 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 1994 | 115 | 0.020 |
Why?
| | Administration, Intranasal | 3 | 1989 | 93 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 1994 | 319 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 191 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2013 | 83 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
| | Specimen Handling | 1 | 2014 | 185 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1867 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.020 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 42 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 111 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 53 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 29 | 0.020 |
Why?
| | Phenytoin | 2 | 1962 | 21 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 152 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1994 | 179 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 89 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 50 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1125 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 389 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1172 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 156 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 251 | 0.020 |
Why?
| | Iron | 3 | 1989 | 359 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 977 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 93 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 732 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 299 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 369 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 46 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 456 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 205 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 199 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 221 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 197 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 271 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 25 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 42 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 255 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 379 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 889 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 128 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 610 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 16 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 34 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 53 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 255 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 150 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 511 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 634 | 0.020 |
Why?
| | California | 1 | 1991 | 469 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 428 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 273 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 35 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 25 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1487 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 254 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 12 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 513 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 758 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 112 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 192 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 28 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 88 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 187 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4562 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 141 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 678 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 226 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 527 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 11 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 112 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 164 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 141 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 268 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 25 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 111 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 33 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 327 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 112 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 49 | 0.020 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 34 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.010 |
Why?
| | MART-1 Antigen | 1 | 2005 | 8 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 71 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 850 | 0.010 |
Why?
| | Hemoglobins | 1 | 1988 | 383 | 0.010 |
Why?
| | Metaproterenol | 1 | 1985 | 1 | 0.010 |
Why?
| | Culture Media | 4 | 1977 | 160 | 0.010 |
Why?
| | Reference Standards | 1 | 2006 | 177 | 0.010 |
Why?
| | Extremities | 1 | 2006 | 140 | 0.010 |
Why?
| | Double-Blind Method | 3 | 1998 | 2025 | 0.010 |
Why?
| | Prospective Studies | 4 | 2005 | 7970 | 0.010 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 442 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 23 | 0.010 |
Why?
| | Platelet Count | 2 | 1986 | 96 | 0.010 |
Why?
| | Lower Extremity | 1 | 2009 | 438 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 47 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 14 | 0.010 |
Why?
| | Fatigue | 1 | 2007 | 361 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 555 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 964 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 422 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 248 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 508 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 399 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 499 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 757 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 155 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 380 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 38 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 306 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 175 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 516 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 150 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 8 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 244 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 419 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 115 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 8 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 171 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 789 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 166 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 36 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1884 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 20 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 8 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 62 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 407 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 16 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 47 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 60 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 618 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 37 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 57 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 768 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 253 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 269 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 421 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 173 | 0.010 |
Why?
| | Pain | 1 | 2007 | 777 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 477 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 49 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 290 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1046 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3403 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 9 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1075 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 222 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 16 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 356 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 148 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 196 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 61 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 152 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 62 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 2 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 82 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 7180 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 405 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 24 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 49 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 176 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 76 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1497 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 640 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 40 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 370 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 379 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 69 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 108 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 60 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 2 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 38 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 170 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 938 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 574 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 74 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 405 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 561 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 674 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 630 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1168 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 62 | 0.010 |
Why?
| | Groin | 1 | 1995 | 13 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 299 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 177 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 6 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 5 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 585 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 2 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 18 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 176 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 27 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 61 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 129 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 24 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 55 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 11774 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 91 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 1767 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 115 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 216 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1982 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 9 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 304 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 115 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 291 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 124 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 390 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 397 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2603 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1335 | 0.000 |
Why?
| | Arm | 2 | 1985 | 109 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 2 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 192 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 88 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 86 | 0.000 |
Why?
| | Ferritins | 1 | 1989 | 69 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 294 | 0.000 |
Why?
| | Perfusion | 1 | 1970 | 250 | 0.000 |
Why?
| | Skin | 1 | 1994 | 754 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 4 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 952 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 37 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 25 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 33 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 36 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 12 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 67 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 49 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 207 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 72 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 3 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 186 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 12 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 25 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 2 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 60 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 55 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5592 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 258 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2879 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2916 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 512 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 179 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 15 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 315 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 13 | 0.000 |
Why?
| | Fever | 1 | 1984 | 311 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 849 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 223 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 397 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 57 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 307 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 364 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 11 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 37 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1759 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 316 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 660 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 207 | 0.000 |
Why?
| | Blood | 1 | 1977 | 109 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 22 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 94 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 320 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1460 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 597 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 19 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 11 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1134 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 58 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 67 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1812 | 0.000 |
Why?
| | Leg | 1 | 1972 | 239 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 65 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 139 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 374 | 0.000 |
Why?
| | Swine | 1 | 1970 | 831 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 880 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|